Barinthus Biotherapeutics

Autoimmune and inflammatory diseases are difficult and often lifelong challenges.

Barinthus Bio is developing novel immunotherapies that reprogram T cells to target the root causes of these conditions. A co-inventor of the Oxford/AstraZeneca COVID-19 vaccine, which was developed in less than a year and saved an estimated 6m lives globally, the company was listed on US NASDAQ in 2021. It’s now applying its immunology expertise to transform care across a broad range of immune-related diseases.